Skip to main content

Chagas Disease

6
Pipeline Programs
11
Companies
16
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 7 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bayer
LAMPITApproved
nifurtimox
Bayer
oral2020

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
1
1
Sacubitril/valsartanPhase 4Small Molecule1 trial
LXE408Phase 21 trial
Active Trials
NCT06632600Recruiting130Est. Sep 2030
NCT04023227Completed922Est. Mar 2025
Bayer
BayerLEVERKUSEN, Germany
1 program
1
LAMPIT(nifurtimox)N/A5 trials
Active Trials
NCT05477953Not Yet Recruiting50Est. Jan 2032
NCT03334838Completed36Est. Jan 2020
NCT03784391Completed3,000Est. Apr 2020
+2 more trials
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Implantable Cardiac MonitorPhase 41 trial
Active Trials
NCT01539161Terminated12Est. Apr 2015
MSD
MSDIreland - Ballydine
1 program
1
PosaconazolePhase 2Small Molecule
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
PosaconazolePhase 2Small Molecule1 trial
Active Trials
NCT01377480Completed120Est. Jan 2015
Labcorp
LabcorpBURLINGTON, NC
1 program
Congenital Transmission of Lineages I and II of Trypanosoma CruziN/A1 trial
Active Trials
NCT01787968Completed28,348Est. Dec 2013
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)N/A1 trial
Active Trials
NCT02646943Completed1,959Est. Aug 2014
Abbott
AbbottABBOTT PARK, IL
1 program
Testing Donor Specimens with ESA ChagasN/A1 trial
Active Trials
NCT01662362Completed63Est. Dec 2012
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
PosaconazolePHASE_2Small Molecule
Rhythm Pharmaceuticals
1 program
Implantable Cardiac MonitorPHASE_4
Novartis
NovartisBASEL, Switzerland
1 program
Sacubitril/valsartanPHASE_4Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
SandozSacubitril/valsartan
MedtronicImplantable Cardiac Monitor
Bayernifurtimox
SandozLXE408
Sharp TherapeuticsPosaconazole
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Bayernifurtimox
Allergy TherapeuticsLongitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)
AbbottTesting Donor Specimens with ESA Chagas

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 35,227 patients across 16 trials

NCT04023227SandozSacubitril/valsartan

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

Start: Dec 2019Est. completion: Mar 2025922 patients
Phase 4Completed
NCT01539161MedtronicImplantable Cardiac Monitor

Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease

Start: Jul 2013Est. completion: Apr 201512 patients
Phase 4Terminated

A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

Start: Jan 2016Est. completion: Aug 2021330 patients
Phase 3Completed

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

Start: Apr 2025Est. completion: Sep 2030130 patients
Phase 2Recruiting

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

Start: Jul 2011Est. completion: Jan 2015120 patients
Phase 2Completed

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Start: Jan 2008Est. completion: Oct 2022112 patients
Phase 2Completed

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

Start: Jun 2019Est. completion: Jan 202036 patients
Phase 1Completed

Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

Start: Dec 2018Est. completion: Jun 201924 patients
Phase 1Completed

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Start: Jun 2018Est. completion: Dec 201848 patients
Phase 1Completed

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients

Start: Dec 2015Est. completion: Aug 201636 patients
Phase 1Completed

Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

Start: Nov 2013Est. completion: Sep 201437 patients
Phase 1Completed

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Start: Dec 2026Est. completion: Jan 203250 patients
N/ANot Yet Recruiting

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Start: Dec 2018Est. completion: Apr 20203,000 patients
N/ACompleted
NCT02646943Allergy TherapeuticsLongitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)

Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)

Start: Jul 2013Est. completion: Aug 20141,959 patients
N/ACompleted
NCT01662362AbbottTesting Donor Specimens with ESA Chagas

Abbott ESA Chagas Assay Post-Market Study

Start: Jul 2012Est. completion: Dec 201263 patients
N/ACompleted
NCT01787968LabcorpCongenital Transmission of Lineages I and II of Trypanosoma Cruzi

Congenital Transmission of Lineages I and II of Trypanosoma Cruzi

Start: Apr 2011Est. completion: Dec 201328,348 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 35,227 patients
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.